港股異動 | 醫渡科技高開7% 旗下HLT攜手兆科眼科開展眼底病變候選藥物關鍵臨牀項目
格隆匯4月14日丨醫渡科技(2158.HK)高開7.17%,報9.75港元,總市值96億港元。消息面上,醫渡科技旗下開心生活科技(以下簡稱“HLT”)與專注於眼科藥物創新研發的兆科眼科(6622.HK)攜手,共同開展TAB014第III期臨牀試驗。2021年底,HLT與兆科眼科曾達成戰略合作意向,本次攜手意味着雙方合作進入關鍵實質性階段。TAB014是中國首款處於臨牀階段、用於治療wAMD患者、基於貝伐單抗的抗體。2019年,中國國家衛生健康委員會醫藥衛生科技發展研究中心已將有關TAB014的臨牀研究及商業化項目列爲重大新藥創制科技重大專項。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.